Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Adamis Pharmaceuticals
WARNING LETTER
•Adamis Pharmaceuticals

Adamis Pharmaceuticals – FDA Warning Letter

Record Details

This Warning Letter, dated June 9, 2010, was issued to Adamis Pharmaceuticals concerning their marketing of Epinephrine Injection 1:1000 (0.3 mg prefilled single dose syringe). The FDA determined that this product is an unapproved new drug, violating sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act, as no FDA-approved application is on file. Additionally, the product is misbranded under section 502(f)(1) of the Act because its labeling lacks adequate directions for use, as it is intended for conditions not amenable to self-diagnosis and treatment by laypersons, and it is not exempt under 21 C.F.R. § 201.115. The introduction of this product into interstate commerce also violates section 301(a) of the Act. Adamis Pharmaceuticals is required to promptly correct these violations, investigate their causes, and prevent recurrence. The firm must notify the FDA within fifteen working days with a plan to cease violative activities, dispose of current inventory, address distributed product, and update Drug Listing files if marketing ceases. Failure to comply may result in legal action, including seizure and injunction, and may impact federal contracts.

Company
Adamis Pharmaceuticals
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Deborah M. Autor (Former FDA Deputy Commissioner)
View Company Profile

ID · b92a4276-70b7-4462-9ec6-1e23be40f9c2

Violation Codes10
21 U.S.C. 321(g)(1)(B)21 U.S.C. 321(g)(1)(C)21 U.S.C. 321(p)21 U.S.C. 331(d)21.U.S.C. 355(a)21 U.S.C. 355(b)21 U.S.C. 355(j)21 U.S.C. 352(f)(1)21 CFR 201.11521 CFR 207.30(a)(2)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Adamis Pharmaceuticals
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.